The Colorado HIV-1 Training Program provides basic, translational and clinical AIDS-related postdoctoral training under the direction of a broadly based group of faculty actively engaged in AIDS research at the University of Colorado Health Sciences Center and affiliated institutions. The Training Program has supported two M.D. or M.O./Ph.D. postdoctoral fellows per year since its inception in 1992. This Institutional Training Grant has provided critical career development support for an outstanding group of I 3 postdoctoral fellows under the direction of 10 different mentors. In this competing renewal application we propose to broaden the trainee pool to include two1 postdoctoral fellows per year with the Ph.D. degree. The proposed inclusion of Ph.D. fellows reflects the substantial increase in Ph.D. fellows currently training in laboratories participating laboratories and to add to the diversity and scientific depth of the Training Program. The Training Program will be coordinated by the Adult Infectious Disease Division. Forty-five participating faculty located within 16 Divisions and/or Departments form the mentor core for potential trainees. The Program will be directed by a Steering Committee composed of six faculty with expertise representative of the areas of training. The success of the program will be evaluated on the basis of the extent to which it facilitates the career development of individuals who become productive members of the AIDS research community.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Institutional National Research Service Award (T32)
Project #
2T32AI007447-11
Application #
6500152
Study Section
Microbiology and Infectious Diseases B Subcommittee (MID)
Program Officer
Sharma, Opendra K
Project Start
1992-09-30
Project End
2007-06-30
Budget Start
2002-07-01
Budget End
2003-06-30
Support Year
11
Fiscal Year
2002
Total Cost
$169,587
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Anderson, Peter L; Liu, Albert Y; Castillo-Mancilla, Jose R et al. (2018) Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy. Antimicrob Agents Chemother 62:
Seifert, Sharon M; Castillo-Mancilla, Jose R; Erlandson, Kristine et al. (2018) Brief Report: Adherence Biomarker Measurements in Older and Younger HIV-Infected Adults Receiving Tenofovir-Based Therapy. J Acquir Immune Defic Syndr 77:295-298
Miller, Shannon M; Miles, Brodie; Guo, Kejun et al. (2017) Follicular Regulatory T Cells Are Highly Permissive to R5-Tropic HIV-1. J Virol 91:
Seifert, Sharon M; Chen, Xinhui; Meditz, Amie L et al. (2016) Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State. AIDS Res Hum Retroviruses 32:981-991
Miles, Brodie; Connick, Elizabeth (2016) TFH in HIV Latency and as Sources of Replication-Competent Virus. Trends Microbiol 24:338-344
Smith, Christiana; Weinberg, Adriana; Forster, Jeri E et al. (2016) Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir. Infect Dis Obstet Gynecol 2016:9848041
Castillo-Mancilla, Jose; Seifert, Sharon; Campbell, Kayla et al. (2016) Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing. Antimicrob Agents Chemother 60:6692-6697
Chen, Xinhui; Castillo-Mancilla, Jose R; Seifert, Sharon M et al. (2016) Analysis of the Endogenous Deoxynucleoside Triphosphate Pool in HIV-Positive and -Negative Individuals Receiving Tenofovir-Emtricitabine. Antimicrob Agents Chemother 60:5387-92
Kohler, Stephanie L; Pham, Michael N; Folkvord, Joy M et al. (2016) Germinal Center T Follicular Helper Cells Are Highly Permissive to HIV-1 and Alter Their Phenotype during Virus Replication. J Immunol 196:2711-22
Meditz, Amie L; Palmer, Claire; Predhomme, Julie et al. (2015) Relationship Between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a Raltegravir Versus a Boosted Atazanavir Regimen. AIDS Res Hum Retroviruses 31:1015-22

Showing the most recent 10 out of 48 publications